In the axon, NRG1 activity is modulated by secretase cleavage, namely BACE (Beta-secretase 1) and TNF-alpha convertase enzyme (TACE), which activates and inactivates the molecule, respectively.17 Interestingly, niacin, nicotinic acid or vitamin B3, have been found to be a TACE activator and thus a putative negative regulator of NRG1 type III in the PNS.18 The extended-release formulation of niacin, Niaspan® (Rebel Distributors Corp.), is a FDA (Food and Drug Administration)-approved medicinal product used for many years to treat dyslipidaemia and atherosclerosis.19 This evidence concerns the gene ADAM17 and atherosclerosis.